Uhmontpellier
Montpellier, 34295, France
NCT Number: NCT04288050
In France, chronic end-stage renal disease affects more than 11,000 new patients each year who will require dialysis or renal transplantation, of whom approximately 22.6% of new cases are related to diabetes. Among them, about 94% are managed by hemodialysis (HD), the others by peritoneal dialysis (PD). In addition, nearly 42% of dialysis patients have diabetes. There are issues related to glycemic control during dialysis and specific to each dialysis technique. Thus, hypoglycemic risk is the main risk observed during hemodialysis sessions, linked in particular to the use of a 1g/L glucose free dialysate, a decrease in renal neoglucogenesis and alterations in metabolic pathways. In addition, long-term glycemic control is difficult to assess in dialysis patients, because of the limitations of HbA1c witch is frequently underestimated.
This can be explained by 2 mechanisms:
* EPO treatment is associated with an increase in the proportion of young érythrocytes * reduction in the lifetime of red blood cells reducing the duration of interaction between glucose and hemoglobin.
The results of studies conducted using continuous glucose measurements over a short period of time (48 hours to 5 days) suggest a benefit in using continuous glucose measurement to detect glycemic fluctuations during dialysis. To our knowledge, no studies have been conducted to evaluate longer-term glycemic control with this technology. In addition, the investigators now have the Freestyle, which allows us to record the continuous measurement of interstitial glucose over a longer period of time and is reimbursed for people on insulin basal-bolus protocol.
Thus, the investigators propose an observational study to evaluate glycemic control during dialysis sessions, but also to analyze the correlation between parameters measured with Freestyle and HbA1c measured routinely, according to the follow-up recommendations in diabetics.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Montpellier, 34295, France
Data : patient data (clinical, biological and additional examinations) on a database registered at the University Hospital of Montpellier, on the secure server.
Demographic characteristics: Age, gender Clinical history: Older diabetes, presence of diabetic retinopathy, diabetic maculopathy, microalbuminuria or proteinuria, older dialysis, type of dialysis, presence of ischemic heart disease, history of stroke, arteriopathy, gastroparesis, diabetic neuropathy, high blood pressure, hypercholesterolemia.
Treatments: diabetes, type of kidney replacement, other treatments
Biological assessment: Creatinemia, DFG, microalbuminuria, HbA1C, Hemoglobinemia, HDL, LDL, triglyceridemia, cholesterol, albuminuria/creatinuria ratio, proteinuria/creatinuria ratio
Patients will sign a non-opposition form.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 12 month
Evaluate the time in range glycemic profile in diabetic patients undergoing dialysis
Time frame: 6 month
Time above range of glycemic target
Time frame: 6 month
Time below range of glycemic target
Time frame: 6 month
Glucose management Indicator
Time frame: 6 month
Number of hypoglycemic events
Time frame: 6 month
mean number of scans on diabetic subjects in Dialysis.
Time frame: 6 month
Evaluate the Delta between measured HbA1c and GMI.
Time frame: 6 month
Evaluate the correlation between average interstitial glucose measured at Freestyle and measured HbA1c.
University Hospital, Montpellier
Other
Evaluation of Glycemic Profiles in Diabetic Patients on Dialysis Under Insulin Balsal-bolus Protocol, Using Freestyle Libre. Observational Prospective Study Without Modification of Management.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07083232
Cardiovascular Diseases, Diabetic
Asyut, Egypt
View Trial DetailsNCT05614115
Chronic Disease, Diabetic
Salt Lake City, Utah, United States
View Trial DetailsNCT04353869
Cardiovascular Complications, Diabetes Mellitus
Paris, France
View Trial DetailsNCT05994651
Behavior, Diabetic
Osmaniye, Korkut Ata University, Turkey (Türkiye)
View Trial Details